ExpreS2ion Biotech Holding AB (publ) (EXPRS2) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to today's presentation where we have the pleasure to present expression biotechnologies. Today's coverage of course the full year report fresh from the press this morning but maybe also besides the financial results some of the many milestones achieved I could see in the news flow in this quarter. To help us through today's presentation and answer questions in the end, we have Ben Fransen, CEO, Keith Alexander, CFO. As always, there's a box down below. Do feel free to ask questions. During the presentation, we will keep most or almost all of the questions at the end, but do feel free to do it now. Do feel free to ask in Danish, and I will try and translate to the best of my ability. But I think for now, I will hand the call over to you, Ben. Thank you very much, Michael. Good morning, everybody. Welcome to Expressions Q4 and Bull Year 2025 results webcast. I'm Ben Fransen, CEO of Expression Biotechnologies, and with me today is our CFO, Keith Hellingcenter. Today, I will walk you through the key updates across our pipeline and partnerships, particularly progress in our HER2 breast cancer immunotherapy and our brain-funded infectious disease programs. Before Keith takes you through the financial results. We'll begin with the pipeline updates and key milestones achieved through Q4 in early 2026. And then Keith will present our financial performance and cash position. And finally, we'll open the call for questions. Q4 was a highly productive quarter across both our proprietary pipeline and partnerships. On the financing side, we carried out a geo11 warrants program exercise with 88.5% subscription rate, bringing in approximately 10.4 million sec and strengthening our capital base. Within the pipeline in breast cancer, we reported updated immunogenicity data fro...